Corresponding Author: Torri D. Metz, MD, MS, University of Utah Health, 30 N 1900 E, SOM 2B200, Salt Lake City, UT 84132 (email@example.com).
Accepted for Publication: January 21, 2022.
Published Online: February 7, 2022. doi:10.1001/jama.2022.1190
Author Contributions: Drs Metz and Clifton had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Metz, Clifton, Hughes, Grobman, Manuck, Longo, Sowles, Clark, Mendez-Figueroa, Gyamfi-Bannerman, Costantine, Tita, Macones.
Acquisition, analysis, or interpretation of data: Metz, Clifton, Hughes, Sandoval, Grobman, Saade, Manuck, Sowles, Clark, Simhan, Rouse, Mendez-Figueroa, Gyamfi-Bannerman, Bailit, Costantine, Sehdev, Tita, Macones.
Drafting of the manuscript: Metz, Clifton, Sandoval.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Clifton, Sandoval.
Obtained funding: Metz, Clifton, Grobman, Saade, Clark, Simhan, Rouse, Tita.
Administrative, technical, or material support: Metz, Clifton, Manuck, Longo, Sowles, Clark, Simhan, Rouse, Mendez-Figueroa, Bailit, Costantine, Tita, Macones.
Supervision: Metz, Clifton, Manuck, Clark, Rouse, Bailit, Sehdev, Tita, Macones.
Conflict of Interest Disclosures: Dr Metz reported receiving personal fees from Pfizer for her role as a medical consultant for a study of SARS-CoV-2 vaccination in pregnancy and grants from Pfizer for her roles as a site principal investigator [PI] for a study of SARS-CoV-2 vaccination in pregnancy and as a site PI for a study of respiratory syncytial virus vaccination in pregnancy, and from Gestvision for her role as a site PI for a preeclampsia study outside the submitted work. Dr Hughes reported receiving personal fees from Merck outside the submitted work. Dr Simhan reported being the co-founder of Naima Health LLC and receiving personal fees from UpToDate outside the submitted work. Dr Costantine reported relationships with Baxter International, Momenta Pharmaceuticals, Progenity, AMAG Pharmaceuticals, and ObsEva. Dr Tita reported receiving grants from Pfizer for a COVID-19 in pregnancy trial outside the submitted work. No other disclosures were reported.
Funding Support: This work is funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (grants UG1 HD087230, UG1 HD027869,UG1 HD027915, UG1 HD034208, UG1 HD040500, UG1 HD040485, UG1 HD053097, UG1HD040544, UG1 HD040545, UG1 HD040560, UG1 HD040512, UG1 HD087192, and U10 HD036801) and the National Center for Advancing Translational Sciences (grant UL1TR001873).
Role of the Funder/Sponsor: The NICHD’s Maternal-Fetal Medicine Units (MFMU) Network is funded by a cooperative agreement between NICHD and the MFMU centers. The NICHD was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review and approval of the manuscript; and decision to submit the manuscript for publication.
Group Information: The members of the NICHD’s MFMU Network are listed in Supplement 4.
Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Data Sharing Statement: Data will be available to others through DASH within 1 year of publication. Access to data will follow requirements in place through DASH.
LD , Ellington
S , Strid
et al. Characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status: United States, January 22-October 3, 2020. Centers for Disease Control and Prevention. Accessed December 1, 2020. https://www.cdc.gov/mmwr/volumes/69/wr/mm6944e3.htm
J , Stallings
E , Bonet
et al; PregCOV-19 Living Systematic Review Consortium. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ
. 2020;370:m3320. doi:10.1136/bmj.m3320PubMedGoogle Scholar
MJ , Gilbert
S , Landon
et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Perioperative antibiotic prophylaxis for nonlaboring cesarean delivery. Obstet Gynecol
. 2009;114(4):752-756. doi:10.1097/AOG.0b013e3181b8f28fPubMedGoogle ScholarCrossref
TD , Clifton
RG , Hughes
et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Disease severity and perinatal outcomes of pregnant patients with coronavirus disease 2019 (COVID-19). Obstet Gynecol
. 2021;137(4):571-580. doi:10.1097/AOG.0000000000004339PubMedGoogle ScholarCrossref
JL , Grobman
WA , Rice
et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Risk-adjusted models for adverse obstetric outcomes and variation in risk-adjusted outcomes across hospitals. Am J Obstet Gynecol
. 2013;209(5):446.e1-446.e30. doi:10.1016/j.ajog.2013.07.019PubMedGoogle ScholarCrossref
EM , Huebner
EM , Taylor
et al; Washington State COVID-19 in Pregnancy Collaborative. Disease severity, pregnancy outcomes, and maternal deaths among pregnant patients with severe acute respiratory syndrome coronavirus 2 infection in Washington State. Am J Obstet Gynecol
. 2021;225(1):77.e1-77.e14. doi:10.1016/j.ajog.2020.12.1221PubMedGoogle ScholarCrossref
CA , Bianco
A , Limaye
et al. Pregnant women with severe or critical coronavirus disease 2019 have increased composite morbidity compared with nonpregnant matched controls. Am J Obstet Gynecol
. 2021;224(5):510.e1-510.e12. doi:10.1016/j.ajog.2020.11.022PubMedGoogle ScholarCrossref
AR , Blanchard
CT , Arora
et al; CWRH COVID-19 Working Group. Maternal and perinatal outcomes associated with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta (B.1.617.2) variant. Obstet Gynecol
. 2021;138(6):842-844. doi:10.1097/AOG.0000000000004607PubMedGoogle ScholarCrossref